Clinical trial · Observational
Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells
Research on the Mechanism of Dasatinib Down-regulates the Expression of PD-1 in CMV-activated NKG2C+NK Cells and Enhances Killing pH + Leukemia Stem Cells.
NCT04991532CI-TRIAL-00053115unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Research on the mechanism of dasatinib down-regulates the expression of PD-1 in CMV-activated NKG2C+NK cells and enhances killing pH + leukemia stem cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Dasatinib group
- description
- the CML patient treated with dasatinib
- label
- Imatinib group
- description
- the CML patient treated with imatinib
Primary outcomes (1)
- measure
- NK cells and T cell activation subsets in CML-CP patients treated with TKI for 2 years
- timeFrame
- 2 years
- description
- NK cells and T cell activation subsets in CML-CP patients treated with TKI for 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \>18 years old, gender is not limited 2. CML-CP patients treated with TKIs 3. No pregnancy was planned during the treatment Exclusion Criteria: 1.The researcher judged that it was not suitable to participate in this study
References
Publications (0)
Data not yet available
No reference posted for this study.